Viatris (VTRS) Non-Current Assets (2019 - 2026)
Viatris (VTRS) posted quarterly Non-Current Assets of $25.9 billion for Q1 2026, down 10.17% year-over-year from $28.9 billion in Q1 2025, and down 5.42% quarter-over-quarter from $27.4 billion in Q4 2025.
Viatris (VTRS) Non-Current Assets (2019 - 2026) Analysis & Trends
Viatris' Non-Current Assets history runs 8 years deep, the most recent figure standing at $25.9 billion for Q1 2026.
- In Q1 2026, Non-Current Assets fell 10.17% year-over-year to $25.9 billion; the TTM figure through Mar 2026 stood at $109.9 billion (down 14.0% YoY), while the FY2025 annual figure was $27.4 billion, down 14.31% from the prior year.
- Non-Current Assets for Q1 2026 stood at $25.9 billion, down from $27.4 billion in the prior quarter.
- The five-year high for Non-Current Assets was $41.7 billion in Q1 2022, with the low at $25.9 billion in Q1 2026.
- The 5-year median for Non-Current Assets is $34.4 billion (2024), against an average of $34.3 billion.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets jumped 7877260.0% in 2022, then dropped 16.38% in 2025.
- Viatris' Non-Current Assets stood at $39.4 billion in 2022, then retreated by 11.88% to $34.7 billion in 2023, then dropped by 7.86% to $32.0 billion in 2024, then slipped by 14.31% to $27.4 billion in 2025, then fell by 5.42% to $25.9 billion in 2026.
- Business Quant data shows VTRS's Non-Current Assets at $25.9 billion in Q1 2026, $27.4 billion in Q4 2025, and $28.0 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 2.96 Bn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 2.87 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.99 Bn |
| Mar 31, 2026 | 25.92 Bn |
| Dec 31, 2025 | 27.40 Bn |
| Sep 30, 2025 | 27.97 Bn |
| Jun 30, 2025 | 28.64 Bn |
| Mar 31, 2025 | 28.85 Bn |
| Dec 31, 2024 | 31.98 Bn |
| Sep 30, 2024 | 33.45 Bn |
| Jun 30, 2024 | 33.54 Bn |
| Mar 31, 2024 | 34.42 Bn |
| Dec 31, 2023 | 34.71 Bn |
| Sep 30, 2023 | 37.81 Bn |
| Jun 30, 2023 | 38.92 Bn |
| Mar 31, 2023 | 39.66 Bn |
| Dec 31, 2022 | 39.39 Bn |
| Sep 30, 2022 | 38.17 Bn |
| Jun 30, 2022 | 39.95 Bn |
| Mar 31, 2022 | 41.72 Bn |
| Dec 31, 2021 | 500,000.00 |
| Sep 30, 2021 | 44.76 Bn |